In addition, targeting both arms of NF-κB signaling may also improve the therapeutic outcome in patients with newly diagnosed high-risk DLBCL displaying mutations in both canonical and non-canonical NF-κB pathways [12, 18, 19, 27, 161]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.